{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:44:49Z","timestamp":1760100289144},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":3676,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1999,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Interleukin\u20102 (IL\u20102) is a cytokine that became available for clinical use with the development of recombinant DNA technology. Patients with resistant or relapsed lymphoid neoplasm have been treated with high\u2010dose IL\u20102 with some responses. The aim of the present study is to determine whether there may be a biological justification for the use of low dose subcutaneous (s.c.) IL\u20102 as maintenance therapy in patients with lymphoid neoplasm in complete remission with high risk of relapse. We treated 15 patients with sc IL\u20102, 4.5 Million International Units (MIU) daily, 5 days per week for 12 consecutive weeks, in the outpatient clinic. This therapy was well tolerated and could be administered in an outpatient regimen. It increased the eosinophil count (<jats:italic>p<\/jats:italic> = 0.009), but the number of granulocytes, monocytes, T\u2010lymphocytes and B\u2010lymphocytes did not change. The number of natural killer (NK) cells increased from 11% to 35% of all lymphocytes during IL\u20102 therapy (<jats:italic>p<\/jats:italic> = 0.0006). Effector lymphokine\u2010activated killer activity (eLAK) also increased from 6 \u00d7 10<jats:sup>\u20103<\/jats:sup> Lytic Units (LU)\/ml to 80 \u00d7 10<jats:sup>\u20103<\/jats:sup> LU\/ml (<jats:italic>p<\/jats:italic> = 0.02). All these changes reached a \u201cplateau\u201d after the 4th week of therapy. The increase in the number of NK cells correlated strongly with the increase in eLAK activity (<jats:italic>r<\/jats:italic> = 0.96, <jats:italic>p<\/jats:italic> &lt;0.0001). Disease\u2010free survival was determined in 14 patients who completed the treatment and compared with historical controls. Patients treated with IL\u20102 had the same relapse risk (median time to relapse 11.1 months, 95% confidence interval 5.5\u201316.6) as did controls (median time to relapse 9.7 months, 95% confidence interval 1\u201327.7) (<jats:italic>p<\/jats:italic> = 0.9). Low dose s.c. IL\u20102 stimulated NK proliferation, which generated cytotoxic activity <jats:italic>in vivo<\/jats:italic> in patients with lymphoid neoplasms. However, these patients did not have a lower risk of disease relapse compared to historical controls.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1999.tb01752.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T10:14:27Z","timestamp":1279448067000},"page":"231-238","source":"Crossref","is-referenced-by-count":7,"title":["Low\u2010dose subcutaneous interleukin\u20102 in patients with minimal residual lymphoid neoplasm disease"],"prefix":"10.1111","volume":"62","author":[{"given":"E.","family":"Gonz\u00e1lez\u2010Barca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gra\u00f1ena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fern\u00e1ndez\u2010Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6367046"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198910000-00008"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199301000-00012"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V83.8.2081.2081","article-title":"Interleukin\u20102 treatment in lymphoma: a phase II multicenter study","volume":"83","author":"Gisselbrecht C","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_7_2","first-page":"283","article-title":"Immunotherapy with interleukin\u20102 with or without lymphokine\u2010activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial","volume":"16","author":"Benyunes M","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_8_2","first-page":"98","article-title":"Treatment of residual disease in acute leukemia patients with recombinant interleukin\u20102 (IL2): Clinical and biological findings","volume":"6","author":"Foa R","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.12.2561.2561"},{"key":"e_1_2_1_10_2","first-page":"6597","article-title":"Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin\u20102","volume":"48","author":"Ellis TM","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_1_11_2","first-page":"185","article-title":"Immunomodulatory properties and toxicity of interleukin\u20102 in patients with cancer","volume":"50","author":"Urba WJ","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199510000-00007"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1995.10.195"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_1_15_2","first-page":"77","article-title":"Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and granulocytes by combining centrifugation and sedimentation at 1 g","volume":"21","author":"Boyum A","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1977.tb00242.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1572"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1200\/JCO.1991.9.12.2110","article-title":"Extended continuous infusion low dose recombinant interleukin\u20102 in advanced cancer: prolonged immunomodulation without significant toxicity","volume":"9","author":"Caliguri MA","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518453"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04824.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1509"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V67.3.722.722","article-title":"Characterization of natural killer cells with antileukemia activity following allogeneneic bone marrow transplantation","volume":"67","author":"Hercend T","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_23_2","first-page":"155","article-title":"The graft\u2010versus leukemia (GVL) phenomenon: Is GVL separable from GVHD","volume":"6","author":"Slavin S","year":"1990","journal-title":"Bone Marrow Transpant"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90271-E"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07671.x"},{"key":"e_1_2_1_26_2","first-page":"2371","article-title":"Correlation between clinical response to interleukin\u20102 therapy and sustained production of tumor necrosis factor","volume":"50","author":"Blay JY","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","first-page":"170","article-title":"Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long term subcutaneous recombinant interleukin\u20102 and recombinant interferon\u2010alpha","volume":"4","author":"Duensing S","year":"1992","journal-title":"Mol Biother"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1999.tb01752.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1999.tb01752.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:06:55Z","timestamp":1698502015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1999.tb01752.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["10.1111\/j.1600-0609.1999.tb01752.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01752.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}